Vance Fowler, MD
Infectious Disease · Durham, NCNPI 1831252600
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,631 of the $43,436 with a category attached, or 98.1%. 6 manufacturers reported payments, led by Genentech, Inc. at 44.8% of the total. Among infectious disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 15 payments — averaging $2895.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$19K
- AstraZeneca$10K
- GSK$8K
- Pfizer$6K
- Intervascular$715
- La Jolla Pharmaceutical Company$128
Across 30 payments — averaging $8220.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$139K
- AstraZeneca$108K
What the payments were for
- Consulting fees$42,63198%
- Travel & lodging$6201%
- Food & beverage$1850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 8 | $19,476 |
| AstraZeneca | 2 | $9,805 |
| GSK | 2 | $7,811 |
| Pfizer | 1 | $5,500 |
| Intervascular | 1 | $715 |
| La Jolla Pharmaceutical Company | 1 | $128 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,436 in reported general payments places this provider in the 90th percentile of 250 infectious disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 68 | $306,283 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 21 | $89,567 |
| PrezcobixDarunavir/Cobicistat | 30 | $78,842 |
| TivicayDolutegravir Sodium | 18 | $40,778 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $35,845 |
| IsentressRaltegravir Potassium | 11 | $25,567 |
| Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium | 24 | $3,394 |
| Cephalexin | 11 | $1,113 |
| Fluconazole | 11 | $963 |
| Amoxicillin | 11 | $221 |
| Ondansetron Hcl | 16 | $169 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Durham
- Cristina GasparettoDurham$613K
- Cameron WolfeDurham$112K
- Gordon CoreyDurham$46K
- Mitchell HorwitzDurham$45K
- Sonali AdvaniDurham$37K
- Christopher WoodsDurham$16K
- Steve TaylorDurham$8K
- Barbara AlexanderDurham$6K
- John PerfectDurham$6K
- Kara McGeeDurham$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.